Enekinragene inzadenovec - Pacira BioSciences
Alternative Names: PCRX201; FX 201 - Flexion Therapeutics; GQ 203; Humantakinogene hadenovecLatest Information Update: 17 Jun 2025
At a glance
- Originator Baylor College of Medicine
- Developer Flexion Therapeutics
- Class Anti-inflammatories; Antirheumatics; Gene therapies
- Mechanism of Action Gene transference; Interleukin-1 receptor antagonist expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 11 Jun 2025 Updated efficacy and adverse event data from a phase I trial in Osteoporosis released by Pacira Biosciences
- 15 May 2025 Updated efficacy and adverse event data from a phase I trial in Osteoporosis released by Pacira Biosciences
- 07 Mar 2025 Phase-I development in Osteoarthritis is ongoing in USA (Intra-articular, Injection) (NCT04119687)